CD8+ TIL has been found to be positive related to a better outcomes concerning survival in breast cancer patients (54), and an optimization on the gut microbiota community brings about a promotion on CD8+ T cell-mediated immunity, thereby indicating a better prognosis and an effective outcome of immunotherapy (14, 67). This evidence concerns the gene CD8A and breast carcinoma.